Parabilis Medicines, Inc. Common Stock · PBLS

Exhibit 99.1 Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in desmoid tumors Reached alignment with the U.S. FDA on dose, regimen and trial design for upcoming PEDESTAL Phase 3 registrational trial in desmoid tumors Initiated a dose-ranging clinical study o…

8-K · 2026-11-12 · 0001193125-26-456892

EX-99.1 2 ck0001657677-ex99_1.htm EX-99.1 EX-99.1 Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors CAMBRIDGE, Mass., August 25, 2026 - Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr.…

8-K · 2026-08-25 · 0001193125-26-365132

Exhibit 1 AGREEMENT Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Parabilis Medicines, Inc. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original. Dated: August 14, 2026 ARCH VENTURE FUND XII, L.P. By: ARCH Venture Part…

SCHEDULE 13G · 2026-08-14 · 0001193125-26-352189

EX-99.1 2 ck0001657677-ex99_1.htm EX-99.1 EX-99.1 Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary HeliconTM platform; received $125M in upfront consid…

8-K · 2026-08-13 · 0001193125-26-347869

EX-99.2 3 ck0001657677-ex99_2.htm EX-99.2 Creating Extraordinary MedicinesDrugging Previously Undruggable Intracellular Drivers of Serious Diseases August 2026 Forward-looking statements & disclaimer PARABILIS MEDICINES This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "in…

8-K · 2026-08-13 · 0001193125-26-347869

Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Parabilis Medicines Certificate Number ZQ00000000 Shares Parabilis Medicines, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT SEE REVERSE FOR CERTAIN DEFINITIONS is the owner of THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT, AVAILABLE ONLINE AT www.computershare.com FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Parabili…

S-1/A · 2026-05-27 · 0001193125-26-242067